Literature DB >> 33425728

Long Non-Coding RNA LINC02747 Promotes the Proliferation of Clear Cell Renal Cell Carcinoma by Inhibiting miR-608 and Activating TFE3.

Xiang Ju1,2, Yangyang Sun1, Feng Zhang2, Xiaohui Wei1, Zhenguo Wang1, Xiaozhou He1.   

Abstract

With the rapid development of biotechnology, long noncoding RNAs (lncRNAs) have exhibited good application prospects in the treatment of cancer, and they may become new treatment targets for cancer. This study aimed to explore lncRNAs in clear cell renal cell carcinoma (ccRCC). Differentially expressed lncRNAs in 54 pairs of ccRCC tissues and para-carcinoma tissues were analyzed in The Cancer Genome Atlas (TCGA), and the most significant lncRNAs were selected and verified in ccRCC tissues. We found that lncRNA LINC02747 was highly expressed in ccRCC (P < 0.001) and was closely related to high TNM stage (P = 0.006) and histological grade (P = 0.004) and poor prognosis of patients (P < 0.001). In vivo and in vitro experiments confirmed that LINC02747 could promote the proliferation of ccRCC cells. We also found that LINC02747 regulated the proliferation of RCC cells by adsorbing miR-608. Subsequent mechanistic research showed that miR-608 is downregulated in ccRCC (P < 0.001), and overexpression of miR-608 inbibited the proliferation of RCC cells. Moreover, we found that TFE3 is a direct target gene of miR-608. MiR-608 regulated the proliferation of RCC cells by inhibiting TFE3. In conclusion, LINC02747 upregulates the expression of TFE3 by adsorbing miR-608, ultimately promoting the proliferation of ccRCC cells. The above findings indicate that LINC02747 acts as an oncogene in ccRCC and may be developed as a molecular marker for the diagnosis and prognosis of ccRCC. The LINC02747/miR-608/TFE3 pathway may become a new therapeutic target for ccRCC.
Copyright © 2020 Ju, Sun, Zhang, Wei, Wang and He.

Entities:  

Keywords:  LINC02747; TFE3 ; ccRCC; ceRNA; miR-608

Year:  2020        PMID: 33425728      PMCID: PMC7786277          DOI: 10.3389/fonc.2020.573789

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  6 in total

1.  Epithelial-mesenchymal transition-related genes in coronary artery disease.

Authors:  Xiang Xu; Renchao Zou; Xiaoyong Liu; Jia Liu; Qianqian Su
Journal:  Open Med (Wars)       Date:  2022-04-22

2.  Identification of a novel immune-related microRNA prognostic model in clear cell renal cell carcinoma.

Authors:  Yuhe Guo; Xianbin Li; Junbin Zheng; Jiali Fang; Guanghui Pan; Zheng Chen
Journal:  Transl Androl Urol       Date:  2021-02

3.  The long non-coding RNA NNT-AS1 promotes clear cell renal cell carcinoma progression via regulation of the miR-137/ Y-box binding protein 1 axis.

Authors:  Yadi Zhou; Zhenghao Zhang; Mingyi Wo; Wenfang Xu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

4.  Identification and Validation of a Ferroptosis-Related Long Non-Coding RNA (FRlncRNA) Signature to Predict Survival Outcomes and the Immune Microenvironment in Patients With Clear Cell Renal Cell Carcinoma.

Authors:  Zhongbao Zhou; Zhenpeng Yang; Yuanshan Cui; Shuai Lu; Yongjin Huang; Xuanyan Che; Liqing Yang; Yong Zhang
Journal:  Front Genet       Date:  2022-03-08       Impact factor: 4.599

Review 5.  Biological Functions and Molecular Mechanisms of MiR-608 in Cancer.

Authors:  Juan Lu; Danhua Zhu; Lanjuan Li
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

6.  A Novel Prognostic Ferroptosis-Related Long Noncoding RNA Signature in Clear Cell Renal Cell Carcinoma.

Authors:  Zhixun Bai; Yongchao Zhao; Xiaomin Yang; Linglu Wang; Xianhua Yin; Yue Chen; Jing Lu
Journal:  J Oncol       Date:  2022-02-22       Impact factor: 4.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.